A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Urothelial Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 48 (planned)
- Started
- Nov 16, 2022
- Main results expected
- Feb 26, 2029
- Fully finished
- Feb 26, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Experienced At Least One Adverse Event (AE)
Measured over: Up to approximately 5 years
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to approximately 5 years
Arm A: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 2 years
Arm B: ORR as Assessed by Investigator
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05562830 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC